Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine.
Respiratory syncytial virus (RSV) causes severe lower respiratory tract disease in infants, young children, and the elderly. Efforts to develop satisfactory live or inactivated vaccines have not yet been proven successful. Our research focuses on the development of four purified live attenuated RSV sub-type A human vaccine clones. Temperature sensitive (ts) and attenuated purified clones of either cold-adapted (ca) RSV or high-passage (hp) RSV were administered intra-nasally (i.n.) to BALB/c mice and tested for immunogenicity. All four clones produced significant anti-RSV F IgG2a and IgG1 titres in the sera of mice, RSV-specific neutralizing titres higher than those produced by their wild-type progenitor viruses, cytotoxic T-lymphocyte (CTL) activity, and total protection against wild-type (wt) viral challenge. These purified vaccine candidates await testing in humans to determine which contain the required balance between immunogenicity and attenuation.
Herlocher
M L
ML
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor 48109-2029, USA.
Ewasyshyn
M
M
Sambhara
S
S
Gharaee-Kermani
M
M
Cho
D
D
Lai
J
J
Klein
M
M
Maassab
H F
HF
D000368:Aged; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D009500:Neutralization Tests; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D013696:Temperature; D014613:Vaccines, Attenuated / Q000276:immunology / Q000302:isolation & purification; D014765:Viral Vaccines / Q000276:immunology* / Q000302:isolation & purification; D014776:Virus Cultivation